Ardena acquisition strengthens API offering8 May 2018
Acquisition enables Ardena to manufacture batch sizes up to 100 kg.
CDMO Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.
The acquisition, which is the CDMO’s first outside the Benelux region, expands its drug substance manufacturing capacity and means that bigger batch sizes up to 100 kg can now be handled by Ardena. Syntagon also adds specialist expertise in GMP chromatographic purification processes to the group.
The announcement follows Ardena’s acquisition of ChemConnection in March 2018 and is part of its strategy to form a leading integrated drug development company and reach the €35 million sales mark this year.
Harry Christiaens, CEO of Ardena, comments: “At Ardena, it is our goal to become a one source contractor by offering an integrated set of services to meet all chemical, pharmaceutical and (bio)analytical needs that arise in the clinical supply chain from lab to patient. This is the driver of our M&A strategy.
“By adding the ChemConnection and Syntagon capabilities to our group, we can now offer specialist technology expertise in drug substance manufacturing.”
Established in 1999, Syntagon has sites in Sweden and Latvia and employs 30 people. This latest acquisition brings the total number of Ardena facilities to six, including its headquarters in Ghent, Belgium and three sites in the Netherlands (Oss, Amsterdam and Assen).
Harry continued: “The Syntagon acquisition gives us a presence in Scandinavia, where we are well positioned to capitalise on the emerging biotech segment and broader pharmaceutical market. With support from our financial investor Mentha Capital, we will continue to focus on both organic growth and acquisition opportunities on our path to create an internationally recognised drug development company.”
Commenting on the acquisition, Michael Lofthagen, CEO at Syntagon added: “Our customers can now benefit from a more integrated service offering, which will ultimately streamline the progress of products through clinical development. We are looking forward to leveraging the synergies across the Ardena group to deliver the best possible offering to the market.”
Middle East and Africa pharma economy to reach US$38.8 billion by 2021
17 Aug 2018
CPhI Middle East & Africa opens in Abu Dhabi as finished dosage formulations expand quickly, driven by government reforms to further increase local manufacturing.Read more
Leaf Expression promises rich harvest for drug industry
16 Aug 2018
Company's multimillion pound purpose-built facility becomes fully operational amidst growing interest worldwide in its potentially game-changing plant transient expression technology, Hypertrans.Read more
Mylan launches first generic for Adcirca tablets
14 Aug 2018
Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability.Read more
Protecting the links between the UK and the EMA
14 Aug 2018
Now less than a year away from when the UK officially leaves the EU, the main goal remains the same - maintaining access to new drugs for patient health.Read more
TraceLink announces Russia compliance solution
13 Aug 2018
Company helps customers navigate and company with "one of the most complicated track and trace regulations in the world".Read more
Exosome isolation manufacturing and characterization
13 Aug 2018
New service to reliably and reproducibly isolate exosomes from almost any biofluid.Read more
Compact serialization-ready manual workstation
11 Aug 2018
A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.Read more
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines
8 Aug 2018
Company moves away from manual processing in favour of automated, scalable platforms.Read more
BASF receives award for its portfolio of natural cosmetic ingredients
7 Aug 2018
Company recognised for its innovation and continual delivery of new natural ingredients.Read more
Extended distribution agreement enables customers to continuously improve their bioprocesses
6 Aug 2018
Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation